Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medication safety

Study supports cardiovascular safety of testosterone

Despite FDA warnings, no link found between testosterone therapy and cardiovascular risks.

Researchers say findings add further evidence supporting the cardiovascular safety of testosterone supplementation in this group of patients. In the image, light micrograph of testosterone hormone

Source: Alfred Pasieka / Science Photo Library

Men whose levels of testosterone have lowered naturally due to ageing are sometimes prescribed hormone therapies off-label

Testosterone therapies are sometimes prescribed off-label to men whose levels of the hormone have lowered naturally due to ageing.

Uncertain benefits and concerns over cardiovascular safety led the US Food and Drug Administration (FDA) to ask manufacturers in March 2015 to clarify the labelling on such products. The FDA also said doctors should only prescribe them to patients with specific medical conditions.

Now, a study presented at the American Heart Association Scientific Sessions[1] in November 2015 has found no evidence that testosterone supplementation in otherwise healthy men increases cardiovascular risks.

The research found that 878 men who received testosterone therapy were less likely to experience a major cardiac event (hazard ratio [HR] 0.37, confidence interval [CI] 0.22-0.61; P<0.0001), and less likely to die (HR 0.27, CI 0.14-0.51; P<0.0001) during three years follow up than the 594 men who did not receive testosterone.

The researchers say their findings add further evidence to support the cardiovascular safety of testosterone supplementation in this group of patients.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200063

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Healthcare Communication

    Healthcare Communication

    Healthcare Communication is an interactive and engaging guide for healthcare professionals. It supports you in establishing rewarding professional relationships.

    £33.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • Traditional Medicine

    Traditional Medicine

    Covers the major traditional medicine systems. Gives information on philosophy, practice, safety, evidence and examples.

    £43.00Buy now
  • MCQs in Pharmacy Practice

    MCQs in Pharmacy Practice

    A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Researchers say findings add further evidence supporting the cardiovascular safety of testosterone supplementation in this group of patients. In the image, light micrograph of testosterone hormone

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.